Publikation:

Predictive biological markers for response of invasive breast cancer to anthracycline / cyclophosphamide-based primary (radio-)chemotherapy

Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2005

Autor:innen

Prisack, Hans-Bernd
Modlich, Olga
Audretsch, Werner
Danae, Mahmoud
Rezai, Mahadi
Bojar, Hans

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
DOI (zitierfähiger Link)
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung

Sammlungen

Biologie: Publikationen
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Anticancer Research. 2005, 25(6C), pp. 4615-4621. ISSN 0250-7005. eISSN 1791-7530

Zusammenfassung

The role of biological markers for the prediction of neoadjuvant chemotherapy and radio-chemotherapy may be evaluated using pathological complete response [pCR] in patients with invasive breast cancer. Materials and Methods: To investigate this, pre-treatment biopsies from 517 patients with locally advanced breast cancer were analyzed for expression of estrogen receptor [ER], progesterone receptor [PgR], Her-2/neu, epidermal growth factor receptor [EGF-R], p53, Bcl-2 and MIB-1 by immunohistochemistry [IHC], and these data were compared to the pathological response after preoperative epirubicine/cyclophosphamide [EC] chemotherapy (+/- radiotherapy). Results: pCR was more frequent (28.3%, 56/198) in tumors that received radio-chemotherapy compared to chemotherapy alone (11.9%, 38/319, p<0.0001). Patients with high grading, lower ER, PgR, Bcl-2 or a higher proliferation had a significantly greater benefit from chemotherapy. The overexpressions of Her2/neu or EGF-R were weakly correlated to pCR, while p53 staining did not have any predictive value. Younger patients, with negative PgR and high proliferation index, had the highest benefit from EC therapy (56% pCR). The different multivariate indices of binary regression, PLS-DA and SIMCA, had similar predictive quality and were slightly superior to univariate factors. Conclusion: This study emphasizes the value of traditional biological markers and Bcl-2 for use in the individual selection of a primary therapy regimen.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

ERα, PgR, proliferation, Bcl-2, Her-2/neu, p53, EGF-R

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690PRISACK, Hans-Bernd, Christiaan KARREMAN, Olga MODLICH, Werner AUDRETSCH, Mahmoud DANAE, Mahadi REZAI, Hans BOJAR, 2005. Predictive biological markers for response of invasive breast cancer to anthracycline / cyclophosphamide-based primary (radio-)chemotherapy. In: Anticancer Research. 2005, 25(6C), pp. 4615-4621. ISSN 0250-7005. eISSN 1791-7530
BibTex
@article{Prisack2005Predi-38812,
  year={2005},
  title={Predictive biological markers for response of invasive breast cancer to anthracycline / cyclophosphamide-based primary (radio-)chemotherapy},
  url={http://ar.iiarjournals.org/content/25/6C/4615.full.pdf+html},
  number={6C},
  volume={25},
  issn={0250-7005},
  journal={Anticancer Research},
  pages={4615--4621},
  author={Prisack, Hans-Bernd and Karreman, Christiaan and Modlich, Olga and Audretsch, Werner and Danae, Mahmoud and Rezai, Mahadi and Bojar, Hans}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/38812">
    <dc:creator>Modlich, Olga</dc:creator>
    <dc:contributor>Karreman, Christiaan</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:03:32Z</dcterms:available>
    <dc:creator>Rezai, Mahadi</dc:creator>
    <dc:creator>Danae, Mahmoud</dc:creator>
    <dcterms:title>Predictive biological markers for response of invasive breast cancer to anthracycline / cyclophosphamide-based primary (radio-)chemotherapy</dcterms:title>
    <dc:contributor>Modlich, Olga</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2005</dcterms:issued>
    <dc:creator>Audretsch, Werner</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:03:32Z</dc:date>
    <dc:contributor>Danae, Mahmoud</dc:contributor>
    <dc:contributor>Bojar, Hans</dc:contributor>
    <dc:creator>Prisack, Hans-Bernd</dc:creator>
    <dc:creator>Karreman, Christiaan</dc:creator>
    <dc:contributor>Audretsch, Werner</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Rezai, Mahadi</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/38812"/>
    <dc:creator>Bojar, Hans</dc:creator>
    <dcterms:abstract xml:lang="eng">The role of biological markers for the prediction of neoadjuvant chemotherapy and radio-chemotherapy may be evaluated using pathological complete response [pCR] in patients with invasive breast cancer. Materials and Methods: To investigate this, pre-treatment biopsies from 517 patients with locally advanced breast cancer were analyzed for expression of estrogen receptor [ER], progesterone receptor [PgR], Her-2/neu, epidermal growth factor receptor [EGF-R], p53, Bcl-2 and MIB-1 by immunohistochemistry [IHC], and these data were compared to the pathological response after preoperative epirubicine/cyclophosphamide [EC] chemotherapy (+/- radiotherapy). Results: pCR was more frequent (28.3%, 56/198) in tumors that received radio-chemotherapy compared to chemotherapy alone (11.9%, 38/319, p&lt;0.0001). Patients with high grading, lower ER, PgR, Bcl-2 or a higher proliferation had a significantly greater benefit from chemotherapy. The overexpressions of Her2/neu or EGF-R were weakly correlated to pCR, while p53 staining did not have any predictive value. Younger patients, with negative PgR and high proliferation index, had the highest benefit from EC therapy (56% pCR). The different multivariate indices of binary regression, PLS-DA and SIMCA, had similar predictive quality and were slightly superior to univariate factors. Conclusion: This study emphasizes the value of traditional biological markers and Bcl-2 for use in the individual selection of a primary therapy regimen.</dcterms:abstract>
    <dc:contributor>Prisack, Hans-Bernd</dc:contributor>
    <dc:language>eng</dc:language>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.
http://ar.iiarjournals.org/content/25/6C/4615.full.pdf+html

Prüfdatum der URL

2017-05-09

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Diese Publikation teilen